Price$87.36-27.92 (-24.22%)
2026-03-052026-06-08
News · 26 weeks52+23%
2025-12-142026-06-07
Mix3890d
- SEC Filings16(42%)
- Other7(18%)
- Insider6(16%)
- Earnings5(13%)
- Analyst2(5%)
- Offering2(5%)
Latest news
25 items- SECCelcuity Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits8-K - Celcuity Inc. (0001603454) (Filer)
- SECSEC Form 424B5 filed by Celcuity Inc.424B5 - Celcuity Inc. (0001603454) (Filer)
- SECSEC Form 305B2 filed by Celcuity Inc.305B2 - Celcuity Inc. (0001603454) (Filer)
- INSIDERChief Science Officer Laing Lance G. exercised 1,000 shares at a strike of $9.89, increasing direct ownership by 0.08% to 1,251,000 units (SEC Form 4)4 - Celcuity Inc. (0001603454) (Issuer)
- SECSEC Form FWP filed by Celcuity Inc.FWP - Celcuity Inc. (0001603454) (Subject)
- PRCelcuity Inc. Announces Pricing of Upsized Public Offering of 0.250% Convertible Senior Notes Due 2032MINNEAPOLIS, June 03, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC) ("Celcuity" or the "Company"), a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid tumor indications, today announced the pricing of its upsized underwritten public offering of $500,000,000 aggregate principal amount of its 0.250% convertible senior notes due 2032 (the "Convertible Notes"). The aggregate principal amount of the offering was increased from the previously announced offering size of $400,000,000. The Company has granted the underwriters of the offering a 30-day option to purchase up to an additional $75,000,000 aggregate principal
- PRCelcuity Inc. Announces Public Offering of Convertible Senior Notes Due 2032MINNEAPOLIS, June 03, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC) ("Celcuity" or the "Company"), a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid tumor indications, today announced a proposed underwritten public offering of $400,000,000 aggregate principal amount of its convertible senior notes due 2032 (the "Convertible Notes"). The Company intends to grant the underwriters of the offering a 30-day option to purchase up to an additional $60,000,000 aggregate principal amount of Convertible Notes, solely to cover over-allotments, if any. The Convertible Notes will be general, unsecured, senior obligations
- SECSEC Form 424B5 filed by Celcuity Inc.424B5 - Celcuity Inc. (0001603454) (Filer)
- PRCelcuity's Gedatolisib Combination Regimens Doubled the Likelihood of Survival without Disease Progression or Death Compared to Alpelisib plus Fulvestrant in the PIK3CA Mutant Cohort of the Pivotal Phase 3 VIKTORIA-1 Trial in Patients with HR+/HER2- Advanced Breast CancerGedatolisib plus fulvestrant and palbociclib (the "gedatolisib-triplet") reduced the risk of disease progression or death by 50% vs. alpelisib plus fulvestrant (HR=0.50; 95% CI: 0.37–0.68; p<0.0001). Median progression-free survival ("PFS") was 11.1 months with the gedatolisib triplet versus 5.6 months with alpelisib plus fulvestrantGedatolisib plus fulvestrant (the "gedatolisib-doublet") reduced the risk of disease progression or death by 49% vs. alpelisib plus fulvestrant (HR=0.51; 95% CI: 0.33–0.79; descriptive p=0.0013). Median PFS was 11.3 months with the gedatolisib-doublet versus 5.6 months with alpelisib plus fulvestrantGedatolisib regimens demonstrated robust and durable responses:
- SECCelcuity Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Celcuity Inc. (0001603454) (Filer)
- PRCelcuity to Hold Conference Call to Discuss Results for the PIK3CA Mutant Cohort of the Phase 3 VIKTORIA-1 Clinical Trial of Gedatolisib Regimens in HR+/HER- Advanced Breast Cancer on June 2, 2026MINNEAPOLIS, June 01, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid tumor indications, today announced it will host a conference call and live webcast to review results from the PIK3CA mutant cohort of the Phase 3 VIKTORIA-1 clinical trial on Tuesday, June 2, 2026 at 8:00 a.m. EDT / 7:00 a.m. CDT. Webcast and Conference Call Information The Celcuity management team will host a live webcast and conference call on Tuesday, June 2, 2026, at 8:00 a.m. EDT / 7:00 a.m. CDT to discuss the results from the Phase 3 VIKTORIA-1 trial. Those who would like to participat
- PRCelcuity To Participate in Upcoming Investor ConferencesMINNEAPOLIS, May 28, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid tumor indications, today announced that Brian Sullivan, Chief Executive Officer and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences: A fireside chat at the Jefferies Global Healthcare Conference at 1:25 p.m. EDT on Thursday, June 4, 2026. A live webcast will be available using this weblink: https://event.summitcast.com/view/NgCqua4VVQjq9ibVWHVWca/CMgAqyC4qKWHVGdLtG2QB8A fireside chat at the Goldman Sachs 47th Annual G
- INSIDERDirector Buller Richard E gifted 1,029 shares and received a gift of 1,029 shares, closing all direct ownership in the company (SEC Form 4)4 - Celcuity Inc. (0001603454) (Issuer)
- SECAmendment: SEC Form 8-K/A filed by Celcuity Inc.8-K/A - Celcuity Inc. (0001603454) (Filer)
- SECSEC Form S-8 filed by Celcuity Inc.S-8 - Celcuity Inc. (0001603454) (Filer)
- SECSEC Form 8-K filed by Celcuity Inc.8-K - Celcuity Inc. (0001603454) (Filer)
- SECSEC Form SCHEDULE 13G filed by Celcuity Inc.SCHEDULE 13G - Celcuity Inc. (0001603454) (Subject)
- SECSEC Form 10-Q filed by Celcuity Inc.10-Q - Celcuity Inc. (0001603454) (Filer)
- SECCelcuity Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Celcuity Inc. (0001603454) (Filer)
- PRCelcuity Inc. Reports Release of First Quarter 2026 Financial Results and Provides Corporate UpdatePhase 3 VIKTORIA-1 trial achieved primary endpoint with clinically meaningful improvement in progression-free survival in PIK3CA mutant cohort; detailed data for gedatolisib regimens will be presented at the 2026 ASCO Annual Meeting Phase 3 VIKTORIA-2 trial expanded to include a second study evaluating gedatolisib as first-line treatment in patients with endocrine-sensitive HR+/HER2- advanced breast cancerDevelopment of a gedatolisib formulation for subcutaneous injection underway; first patent application submitted to the U.S. Patent and Trademark OfficeManagement to host webcast and conference call today, May 14, 2026, at 4:30 p.m. EDT MINNEAPOLIS, May 14, 2026 (GLOBE NEWSWIRE) -- Celc
- PRCelcuity's Phase 3 VIKTORIA-2 Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer Expanding to Include Endocrine-Sensitive PatientsMINNEAPOLIS, May 14, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid tumor indications, today announced updates to the Phase 3 VIKTORIA-2 clinical trial of gedatolisib as a first-line treatment for patients with hormone receptor positive ("HR+"), human epidermal growth factor receptor 2 negative ("HER2-") locally advanced or metastatic breast cancer ("ABC"). Following last year's announcement and subsequent data presentation demonstrating clinically meaningful improvement in progression-free survival ("PFS") for patients treated with gedatolisib combined with p
- PRCelcuity Schedules Release of First Quarter 2026 Financial Results and Webcast/Conference CallMINNEAPOLIS, May 07, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the first quarter 2026 after the market closes on Thursday, May 14, 2026. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. Webcast and Conference Call Information To participate in the teleconference, domestic callers should dial 1-800-717-1738 and international callers should dial 1-646-307-1865. A live webcast presentation can also be accessed using this weblink: htt
- INSIDERDirector Dalvey David sold $3,517,000 worth of shares (25,000 units at $140.68) as part of a pre-agreed trading plan (SEC Form 4)4 - Celcuity Inc. (0001603454) (Issuer)
- INSIDERDirector Buller Richard E exercised 9,000 shares at a strike of $5.10 and sold $1,264,181 worth of shares (9,000 units at $140.46) as part of a pre-agreed trading plan (SEC Form 4)4 - Celcuity Inc. (0001603454) (Issuer)
- SECSEC Form 144 filed by Celcuity Inc.144 - Celcuity Inc. (0001603454) (Subject)
CELC FAQ
7 questionsWhat does Celcuity Inc. do?
Celcuity Inc., a clinical stage biotechnology company, discovers cancer sub-types and therapeutic options for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis...Where does CELC stock trade?
Celcuity Inc. (CELC) is listed on NASDAQ.What sector and industry is CELC in?
Celcuity Inc. operates in the Health Care sector, Medical Specialities industry.When did Celcuity Inc. go public?
Celcuity Inc. (CELC) completed its IPO in 2017.What are analysts saying about CELC?
Celcuity Inc. has had 8 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy on 2026-05-04. Recent price targets range from $2900.00 to $3000.00.What companies are similar to CELC?
Notable peers in the same industry include UNH (UnitedHealth Group Incorporated), ANTM (Anthem Inc.), ELV (Elevance Health Inc.), CI (The Cigna Group), HUM (Humana Inc.). Compare CELC side-by-side with any of them on Quantisnow.How can I track CELC on Quantisnow?
Quantisnow aggregates Celcuity Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CELC to receive live email and push alerts on every new disclosure.